Please use this identifier to cite or link to this item:
A Perspective on the Development of Plant-Made vaccines in the Fight against ebola virus
Carlos Eliud Angulo Valadez
Acceso Abierto
ISSN: 1664-3224
DOI: 10.3389/fimmu.2017.00252
Ebola virus, mucosal immunization, low-cost vaccine, global vaccination, molecular pharming, glycoprotein antigen, VP antigen
"The Ebola virus (EBOV) epidemic indicated a great need for prophylactic and therapeutic strategies. The use of plants for the production of biopharmaceuticals is a concept being adopted by the pharmaceutical industry, with an enzyme for human use currently commercialized since 2012 and some plant-based vaccines close to being commercialized. Although plant-based antibodies against EBOV are under clinical evaluation, the development of plant-based vaccines against EBOV essentially remains an unexplored area. The current technologies for the production of plant-based vaccines include stable nuclear expression, transient expression mediated by viral vectors, and chloroplast expression. Specific perspectives on how these technologies can be applied for developing anti- EBOV vaccines are provided, including possibilities for the design of immunogens as well as the potential of the distinct expression modalities to produce the most relevant EBOV antigens in plants considering yields, posttranslational modifications, production time, and downstream processing."
Frontiers Media, S. A.
Frontiers in Immunology
Rosales-Mendoza S, Nieto-Gómez R and Angulo C (2017) A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus. Front. Immunol. 8:252
Versión publicada
publishedVersion - Versión publicada
Appears in Collections:Artículos

Upload archives

File SizeFormat 
rosales_s2017.pdf675.4 kBAdobe PDFView/Open